20 Jun 2016 --- Metagenics, Inc., a lifestyle functional nutrition company, announced novel clinical results of a randomized controlled research study using Ultra Glucose Control Medical Food.
The diabetes-specific nutritional formula, in combination with a dietary and exercise plan, can play a key role in glycemic control, as well as help to deliver greater reductions to A1C levels (which provides information about a person's average levels of blood glucose) in overweight and obese patients with Type 2 diabetes, compared to the standard of care of dietary management alone.
These clinically significant results presented at American Diabetes Association’s 76th Scientific Sessions in New Orleans, Louisiana.
The randomized clinical study showed that the use of Ultra Glucose Control Medical Food, along with a dietary plan and exercise resulted in 0.63%-0.67% reduction in A1C levels; whereas, dietary planning alone resulted in no change of A1C levels.
“Effective management of A1C levels, while challenging, is critical to reducing the risk of diabetes-related complications," said Osama Hamdy, M.D., Ph.D., FACE, medical director of the Obesity Clinical Program and Director of the Inpatient Diabetes Program at the Joslin Diabetes Center.
“This data is encouraging, as overweight adults with Type 2 diabetes now have a more effective approach to reducing A1C and body weight through a structured dietary plan that includes Ultra Glucose Control.”
The study compared the effect of three Medical Nutrition Therapy models on A1C and body weight in 108 overweight and obese adults with uncontrolled Type 2 diabetes randomized into 3 equal groups over a period of 16 weeks.
Group A met with a registered dietitian (RD) to develop individualized eating plans; Group B met with an RD to receive a structured meal plan that includes menu books, keeping a food log, and using 1-3 servings of Ultra Glucose Control per day as calorie replacements; and Group C followed a plan similar to Group B in addition to receiving weekly phone coaching by RD.
Compared to baseline, A1C did not change in Group A while significantly decreasing in Groups B (-0.63±0.18%, p<0.001) and C (-0.67±0.19%, p<0.001). Change in A1C was significantly different between groups (p=0.0006). Body weight non-significantly decreased in Group A, but significantly decreased in Group B (-3.49±0.73 kg, p<0.001) and Group C (-2.73±0.78 kg, p<0.001). Weight reduction was not different between the 3 groups.
This research follows another recent study conducted by the Joslin Diabetes Center evaluating glucose and insulin response to oatmeal versus commercially available diabetes-specific formulas. The study’s findings demonstrated that Ultra Glucose Control delivered a sustained and significantly lower glucose response over 4 hours that was superior to other commercially available formulas.